Duchenne Muscular Dystrophy - Pipeline Review, H1 2018

  • ID: 4473128
  • Drug Pipelines
  • 305 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akashi Therapeutics Inc
  • CRISPR Therapeutics
  • Fulcrum Therapeutics Inc
  • Marina Biotech Inc
  • NS Pharma Inc
  • Sarepta Therapeutics Inc
  • MORE
Duchenne Muscular Dystrophy - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2018, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 17, 10, 47 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 9 and 1 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akashi Therapeutics Inc
  • CRISPR Therapeutics
  • Fulcrum Therapeutics Inc
  • Marina Biotech Inc
  • NS Pharma Inc
  • Sarepta Therapeutics Inc
  • MORE
Introduction

Duchenne Muscular Dystrophy - Overview

Duchenne Muscular Dystrophy - Therapeutics Development

Duchenne Muscular Dystrophy - Therapeutics Assessment

Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development

Duchenne Muscular Dystrophy - Drug Profiles

Duchenne Muscular Dystrophy - Dormant Projects

Duchenne Muscular Dystrophy - Discontinued Products

Duchenne Muscular Dystrophy - Product Development Milestones

Appendix

List of Tables:

Number of Products under Development for Duchenne Muscular Dystrophy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Akashi Therapeutics Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Antisense Therapeutics Ltd, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Beech Tree Labs Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Biogen Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Bioleaders Corp, H1 2018

Duchenne Muscular Dystrophy - Pipeline by BioMarin Pharmaceutical Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Biophytis SAS, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by CRISPR Therapeutics, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Cumberland Pharmaceuticals Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Debiopharm International SA, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Editas Medicine Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Eloxx Pharmaceuticals Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Duchenne Muscular Dystrophy - Pipeline by FibroGen Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Fulcrum Therapeutics Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Genethon SA, H1 2018

Duchenne Muscular Dystrophy - Pipeline by GTx Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by GW Pharmaceuticals Plc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Italfarmaco SpA, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Marina Biotech Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Mitobridge Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Mitochon Pharmaceuticals Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by N-Gene Research Laboratories Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by NicOx SA, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Nobelpharma Co Ltd, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Novartis AG, H1 2018

Duchenne Muscular Dystrophy - Pipeline by NS Pharma Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by PeptiDream Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Pfizer Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Pluristem Therapeutics Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Prothelia Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by SOM Biotech SL, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Strykagen Corp, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Summit Therapeutics Plc, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018

Duchenne Muscular Dystrophy - Pipeline by Teijin Pharma Ltd, H1 2018

Duchenne Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd, H1 2018

Duchenne Muscular Dystrophy - Dormant Projects, H1 2018

Duchenne Muscular Dystrophy - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Duchenne Muscular Dystrophy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Akashi Therapeutics Inc
  • Antisense Therapeutics Ltd
  • Beech Tree Labs Inc
  • Biogen Inc
  • Bioleaders Corp
  • BioMarin Pharmaceutical Inc
  • Biophytis SAS
  • Capricor Therapeutics Inc
  • Catabasis Pharmaceuticals Inc
  • CRISPR Therapeutics
  • Cumberland Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • Editas Medicine Inc
  • Eloxx Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • FibroGen Inc
  • Fulcrum Therapeutics Inc
  • Galapagos NV
  • Genethon SA
  • GTx Inc
  • GW Pharmaceuticals Plc
  • Italfarmaco SpA
  • Marina Biotech Inc
  • Milo Biotechnology LLC
  • Mitobridge Inc
  • Mitochon Pharmaceuticals Inc
  • N-Gene Research Laboratories Inc
  • NicOx SA
  • Nobelpharma Co Ltd
  • Novartis AG
  • NS Pharma Inc
  • PeptiDream Inc
  • Pfizer Inc
  • Pluristem Therapeutics Inc
  • Prothelia Inc
  • PTC Therapeutics Inc
  • ReveraGen BioPharma Inc
  • Santhera Pharmaceuticals Holding AG
  • Sarepta Therapeutics Inc
  • SOM Biotech SL
  • Strykagen Corp
  • Summit Therapeutics Plc
  • Taiho Pharmaceutical Co Ltd
  • Teijin Pharma Ltd
  • WAVE Life Sciences Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll